COMMUNIQUÉS West-GlobeNewswire
-
Konica Minolta Healthcare Expands Service Offerings and Updates AeroRemote Insights with In-Depth Analytics and Operational Intelligence to Help Facilities Address Current Department Challenges
03/06/2026 -
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
03/06/2026 -
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
03/06/2026 -
Denovo to Participate in Upcoming Investor Conferences Highlighting its Biomarker Guided Phase 3 Antidepressant
03/06/2026 -
Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
03/06/2026 -
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
03/06/2026 -
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
03/06/2026 -
Noah Medical Appoints Dr. Krish Bhadra as Chief Pulmonary Advisor
03/06/2026 -
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
03/06/2026 -
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
03/06/2026 -
RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities
03/06/2026 -
Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
03/06/2026 -
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
03/06/2026 -
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
03/06/2026 -
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
03/06/2026 -
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
03/06/2026 -
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
03/06/2026 -
Mammogen Secures Up to $30 Million Series A Financing Backed by Leading U.S. Public Retirement System to Advance Blood-Based RNA Breast Cancer Detection Platform
03/06/2026 -
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/06/2026
Pages